Aerie Pharmaceuticals Inc. buy melinda
Start price
18.09.18
/
50%
€51.64
Target price
26.09.18
€54.80
Performance (%)
6.20%
End price
26.09.18
€54.84
Summary
This prediction ended on 26.09.18 with a price of €54.84. The BUY prediction by melinda finished with a performance of 6.20%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Aerie Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | -3.033% | -0.013% | 11.953% | 15.609% |
| iShares Nasdaq 100 | -3.554% | -2.546% | 30.128% | 44.540% |
| iShares Nikkei 225® | -3.938% | 2.183% | 11.741% | 8.345% |
| iShares S&P 500 | -1.517% | -0.882% | 25.752% | 42.388% |
Comments by melinda for this prediction
In the thread Aerie Pharmaceuticals Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 19/09 | 17:55 Présentation
Manufactures pharmaceutical products
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
Nombre d'employés : 160 personnes.
Stopped prediction by melinda for Aerie Pharmaceuticals Inc.
Aerie Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€56.15
11.10.17
11.10.17
€63.14
11.04.18
11.04.18
-16.39%
11.04.18
11.04.18
Aerie Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€62.25
11.10.17
11.10.17
€70.00
11.04.18
11.04.18
-16.39%
11.04.18
11.04.18
Aerie Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€46.72
25.09.17
25.09.17
€53.22
11.10.17
11.10.17
23.19%
11.10.17
11.10.17
Aerie Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€51.80
25.09.17
25.09.17
€59.00
11.10.17
11.10.17
23.19%
11.10.17
11.10.17
Aerie Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€50.47
26.05.17
26.05.17
€54.12
15.09.17
15.09.17
7.24%
15.09.17
15.09.17
Aerie Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€55.95
26.05.17
26.05.17
€60.00
15.09.17
15.09.17
7.24%
15.09.17
15.09.17
Aerie Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€39.73
27.01.17
27.01.17
€41.49
09.02.17
09.02.17
5.11%
09.02.17
09.02.17
Aerie Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€8.21
02.05.15
02.05.15
€10.00
29.06.15
29.06.15
93.22%
29.06.15
29.06.15